With Dendreon Humbled, Lessons Learned For Cancer Vaccine Makers
Executive Summary
Problems that led to the capsizing of Dendreon Corp.’s Provenge prostate cancer immunotherapy are particular to the company and product, some cancer vaccine makers are quick to say. Nevertheless, what the Street saw as a commercial disaster for the pioneering treatment bears lessons for those who follow in the budding space.
You may also be interested in...
Sponsors Drive CARs To The Next Destination: Pivotal Trials
With proof of high response rates in small studies of B-cell malignancies in the rear view, sponsors focus on the next hurdles – launching potentially registrational studies in 2015, honing plans for a smooth-running manufacturing process and branching out into new indications.
Juno Launches With Competing Immunotherapy Programs
The latest data from early cancer immunotherapy trials show patients in complete remission, reinforcing the field’s most-watched status. Juno Therapeutics is raising a war chest to capture programs from rival oncology research centers, but it doesn’t mean the competition has ended.
Embracing Rival Programs, Juno Ventures Forth With Talk Of Cancer Cure
The richly funded start-up is an unlikely collaboration between rival oncology research centers, both with immunotherapy programs that require complicated cell therapy processes. Coming together under one roof doesn’t mean the competition has ended.